	Application No.	Applicant(s)
Notice of Allowability		
	10/702,676	LU ET AL. Art Unit
nodes of Allowasing	Examiner	Art Unit
	Tracy Vivlemore	1635
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this a or other appropriate communication IGHTS. This application is subject	pplication. If not included on will be mailed in due course. THIS
1. 🛮 This communication is responsive to the after-final reply su	ubmitted July 19, 2006.	
2. \boxtimes The allowed claim(s) is/are <u>95,97-105,107-122,124-131, 15</u>	33-158 and 161-169.	
3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	s Amendment / Comment or in the	Office action of
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal	Patent Application
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summar	• •
,	Paper No./Mail D 7. ⊠ Examiner's Amend	ate .
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 6/7/06 	1. M Examiner's Amend	ameno Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material		nent of Reasons for Allowance
	9. 🗍 Other	
		SCHULTZ, PH.D. Z RY EXAMINER

Application/Control Number: 10/702,676

Art Unit: 1635

EXAMINER'S AMENDMENT

An extension of time under 37 CFR 1.136(a) is required in order to make an examiner's amendment which places this application in condition for allowance. During a telephone conversation conducted on October 6, 2006, Paul Rauch requested an extension of time for 3 MONTH(S) and authorized the Director to charge Deposit Account No. 50-3123 the required fee of \$510.00 for this extension and authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claims 96, 106, 123, 132, 159 and 160 are canceled.

In claim 109, the word "108" is changed to --107--.

In claims 113, 114, 136 and 137, the phrase "nucleic acid" in line 1 is changed to --product--.

Claim 121 has been re-written as follows: "The method of claim 95 wherein the nucleic acid enzyme is part of an array of nucleic acid enzymes."

Claim 149 has been re-written as follows: "The method of claim 140 wherein the method has a selectivity for Pb²⁺ greater than 80 fold over other divalent metal ions."

Claim 157 has been re-written as follows: "The method of claim 145 wherein the method has a selectivity for Pb²⁺ greater than 80 fold over other divalent metal ions."

Claim 162 has been re-written as follows: "The method of claim 146 wherein the method has a selectivity for Pb²⁺ greater than 80 fold over other divalent metal ions."

Application/Control Number: 10/702,676

Art Unit: 1635

Claim 167 has been re-written as follows: "The method of claim 154 wherein the

Page 3

method has a selectivity for Pb²⁺ greater than 80 fold over other divalent metal ions."

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Tracy Vivlemore whose telephone number is 571-272-

2914. The examiner can normally be reached on Mon-Fri 8:45-5:15.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Peter Paras can be reached on 571-272-4517. The fax phone number for

the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Tracy Vivlemore Examiner

Art Unit 1635

TV

October 4, 2006